OBJECTIVE: Preoperative thrombocytosis has been implicated as a negative prognostic marker for epithelial ovarian cancer (EOC). We assessed whether thrombocytosis is an independent risk factor for EOC recurrence and death. METHODS: Perioperative patient characteristics and process-of-care variables (National Surgical Quality Improvement Program (NSQIP)-defined) were retrospectively abstracted from 587 women who underwent EOC staging between 1/2/03-12/29/08. Thrombocytosis was defined as platelet count > 450 × 10(9)/L. Disease-free survival (DFS) and overall survival (OS) were determined using Kaplan-Meier methods. Associations were evaluated with Cox proportional hazards regression and hazard ratios (HR). RESULTS: The incidence of preoperative thrombocytosis was 22.3%. DFS was 70.8% and 36.0% at 1 and 3 years. OS was 83.3% and 54.3% at 1 and 3 years. Ascites, lower hemoglobin, advanced disease, and receipt of perioperative packed red blood cell transfusion were independently associated with thrombocytosis. Older age and the presence of coronary artery disease were associated with lower likelihood of thrombocytosis. Overall, thrombocytosis was an independent predictor of increased risk of recurrence. Among early stage (I/II) cases, there was a 5-fold increase in the risk of death and nearly 8-fold risk of disease recurrence independently associated with thrombocytosis. CONCLUSION: Preoperative thrombocytosis portends worse DFS in EOC. In early stage disease, thrombocytosis is a potent predictor of worse DFS and OS and further assessment of the impact of circulating platelet-derived factors on EOC survival is warranted. Thrombocytosis is also associated with extensive initial disease burden, measurable residual disease, and postoperative sequelae. Preoperative platelet levels may have value in primary cytoreduction counseling.
OBJECTIVE:Preoperative thrombocytosis has been implicated as a negative prognostic marker for epithelial ovarian cancer (EOC). We assessed whether thrombocytosis is an independent risk factor for EOC recurrence and death. METHODS: Perioperative patient characteristics and process-of-care variables (National Surgical Quality Improvement Program (NSQIP)-defined) were retrospectively abstracted from 587 women who underwent EOC staging between 1/2/03-12/29/08. Thrombocytosis was defined as platelet count > 450 × 10(9)/L. Disease-free survival (DFS) and overall survival (OS) were determined using Kaplan-Meier methods. Associations were evaluated with Cox proportional hazards regression and hazard ratios (HR). RESULTS: The incidence of preoperative thrombocytosis was 22.3%. DFS was 70.8% and 36.0% at 1 and 3 years. OS was 83.3% and 54.3% at 1 and 3 years. Ascites, lower hemoglobin, advanced disease, and receipt of perioperative packed red blood cell transfusion were independently associated with thrombocytosis. Older age and the presence of coronary artery disease were associated with lower likelihood of thrombocytosis. Overall, thrombocytosis was an independent predictor of increased risk of recurrence. Among early stage (I/II) cases, there was a 5-fold increase in the risk of death and nearly 8-fold risk of disease recurrence independently associated with thrombocytosis. CONCLUSION:Preoperative thrombocytosis portends worse DFS in EOC. In early stage disease, thrombocytosis is a potent predictor of worse DFS and OS and further assessment of the impact of circulating platelet-derived factors on EOC survival is warranted. Thrombocytosis is also associated with extensive initial disease burden, measurable residual disease, and postoperative sequelae. Preoperative platelet levels may have value in primary cytoreduction counseling.
Authors: A Radziwon-Balicka; C Medina; L O'Driscoll; A Treumann; D Bazou; I Inkielewicz-Stepniak; A Radomski; H Jow; M W Radomski Journal: Br J Pharmacol Date: 2012-10 Impact factor: 8.739
Authors: Robert F Ozols; Brian N Bundy; Benjamin E Greer; Jeffrey M Fowler; Daniel Clarke-Pearson; Robert A Burger; Robert S Mannel; Koen DeGeest; Ellen M Hartenbach; Rebecca Baergen Journal: J Clin Oncol Date: 2003-07-14 Impact factor: 44.544
Authors: L Manenti; P Paganoni; I Floriani; F Landoni; V Torri; A Buda; G Taraboletti; R Labianca; D Belotti; R Giavazzi Journal: Eur J Cancer Date: 2003-09 Impact factor: 9.162
Authors: Min Soon Cho; Justin Bottsford-Miller; Hernan G Vasquez; Rebecca Stone; Behrouz Zand; Michael H Kroll; Anil K Sood; Vahid Afshar-Kharghan Journal: Blood Date: 2012-09-10 Impact factor: 22.113
Authors: Andrew J Li; Alison C Madden; Ilana Cass; Ronald S Leuchter; Leo D Lagasse; Beth Y Karlan Journal: Gynecol Oncol Date: 2004-01 Impact factor: 5.482
Authors: Rebecca L Stone; Alpa M Nick; Iain A McNeish; Frances Balkwill; Hee Dong Han; Justin Bottsford-Miller; Rajesha Rupairmoole; Guillermo N Armaiz-Pena; Chad V Pecot; Jermaine Coward; Michael T Deavers; Hernan G Vasquez; Diana Urbauer; Charles N Landen; Wei Hu; Hannah Gershenson; Koji Matsuo; Mian M K Shahzad; Erin R King; Ibrahim Tekedereli; Bulent Ozpolat; Edward H Ahn; Virginia K Bond; Rui Wang; Angela F Drew; Francisca Gushiken; Donald Lamkin; Katherine Collins; Koen DeGeest; Susan K Lutgendorf; Wah Chiu; Gabriel Lopez-Berestein; Vahid Afshar-Kharghan; Anil K Sood Journal: N Engl J Med Date: 2012-02-16 Impact factor: 91.245
Authors: Melissa A Merritt; Megan S Rice; Mollie E Barnard; Susan E Hankinson; Ursula A Matulonis; Elizabeth M Poole; Shelley S Tworoger Journal: Lancet Oncol Date: 2018-07-18 Impact factor: 41.316
Authors: Justin Bottsford-Miller; Hyun-Jin Choi; Heather J Dalton; Rebecca L Stone; Min Soon Cho; Monika Haemmerle; Alpa M Nick; Sunila Pradeep; Behrouz Zand; Rebecca A Previs; Chad V Pecot; Erin King Crane; Wei Hu; Susan K Lutgendorf; Vahid Afshar-Kharghan; Anil K Sood Journal: Clin Cancer Res Date: 2014-12-03 Impact factor: 12.531